Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Courtney

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Cancer Immunology Research|January 17, 2025
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector FunctionGengwen Tian, Gabriel A Barragan, Hangjin Yu, et al.
Nature Medicine|October 13, 2020
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysisAndras Heczey, Amy N Courtney, Antonino Montalbano, et al.
Cancer Immunology Research|December 9, 2022
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T CellsHo Ngai, Gabriel A Barragan, Gengwen Tian, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cellsDanielle Fontenot, Hong He, Shino Hanabuchi, et al.
Journal for Immunotherapy of Cancer|January 12, 2025
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15Gengwen Tian, Amy N Courtney, Hangjin Yu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 11, 2026
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activityGabriel A Barragán Bravo, David A de la Cerda, Elisa Landoni, et al.
Nature Medicine|January 9, 2024
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Nature Medicine|May 15, 2023
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Cancer Immunology Research|January 17, 2025
PRDM1 Is a Key Regulator of the NKT-cell Central Memory Program and Effector FunctionGengwen Tian, Gabriel A Barragan, Hangjin Yu, et al.
Nature Medicine|October 13, 2020
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysisAndras Heczey, Amy N Courtney, Antonino Montalbano, et al.
Cancer Immunology Research|December 9, 2022
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T CellsHo Ngai, Gabriel A Barragan, Gengwen Tian, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cellsDanielle Fontenot, Hong He, Shino Hanabuchi, et al.
Journal for Immunotherapy of Cancer|January 12, 2025
Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15Gengwen Tian, Amy N Courtney, Hangjin Yu, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 11, 2026
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activityGabriel A Barragán Bravo, David A de la Cerda, Elisa Landoni, et al.
Nature Medicine|January 9, 2024
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Nature Medicine|May 15, 2023
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim resultsAndras Heczey, Xin Xu, Amy N Courtney, et al.
Research Square|April 22, 2024
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Nature|November 28, 2024
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancersDavid Steffin, Nisha Ghatwai, Antonino Montalbano, et al.
Pageof 4